Clinical Trial Update: Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II dose-escalation trial evaluating Velcade (bortezomib) in combination with docetaxel in patients with advanced androgen-independent prostate cancer; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Velcade (bortezomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Prostatic Neoplasms | Phase 1, Phase 2 | Status: COMPLETED